Ro
Ro runs a vertically integrated platform of telehealth, labs and its own pharmacy, covering diagnosis, medication delivery and ongoing care. It sells directly to consumers, mainly through subscription-style telehealth visits and recurring medication fulfillment, including GLP-1 weight-loss programs. It was founded in 2017 and raised about $1.03B in total. That includes a $500M Series D in March 2021 at a $5B valuation and a 2022 extension at roughly $7B. Sacra estimates 2024 annualized revenue of about $598M, up 66% from about $360M in 2023. Ro is a healthcare company, not an AI company.
Funding
Every round, secondary, debt facility or acquisition involving Ro that AI Lounge tracks, newest first.
No rounds recorded yet.
Members see every AI company on AI Lounge with revenue, funding, valuation and investors, searchable and sortable, free.
Create my free account →Log in